Rationale for FDA’s Position on the Use of Cefazolin Breakpoints as a Surrogate for Determining Breakpoints for Oral Cephalosporins for the Treatment

FDA · Oct 25, 2022

Rationale for FDA’s Position on the Use of Cefazolin Breakpoints as a Surrogate for Determining Breakpoints for Oral Cephalosporins for the Treatment of Uncomplicated Urinary Tract Infections

Baca selengkapnya di : http://www.fda.gov...

Rationale for FDA’s Position on the Use of Cefazolin Breakpoints as a Surrogate for Determining Breakpoints for Oral Cephalosporins for the Treatment

FDA

Guest